D-0308-2021 Class II Terminated

Recalled by Breckenridge Pharmaceutical, Inc — Berlin, CT

FDA drug recall D-0308-2021 was initiated by Breckenridge Pharmaceutical, Inc on March 11, 2021 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out-of-Specification results obtained for unknown impurities during stability testing. The recall status is terminated (terminated March 23, 2022). Affected quantity: 3,146 bottles.

Recall Details

Product Type
Drugs
Report Date
March 24, 2021
Initiation Date
March 11, 2021
Termination Date
March 23, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,146 bottles

Product Description

Omeprazole Delayed-Release Capsules, USP, 20 mg, 1000 count bottles, Rx Only, distributed by Breckenridge Pharmaceutical, Inc., Berlin, CT, Manufactured by Tow Pharmaceutical Europe, S.L., Martorelles (Barcelona), Spain NDC 51991-643-10

Reason for Recall

Failed Impurities/Degradation Specifications: Out-of-Specification results obtained for unknown impurities during stability testing.

Distribution Pattern

Product was distributed nationwide

Code Information

Lot # 191659, exp. date 05/2021